左西孟旦治疗难治性心力衰竭的临床效果

Clinical effect of Levosimendan in the treatment of refractory heart failure

目的研究左西孟旦治疗难治性心力衰竭的临床效果。方法随机抽取2017年9月～2018年6月我院收治的98例难治性心力衰竭患者作为研究对象,采用随机综合平衡法将其分为参照组和实验组,每组各49例。参照组患者采用盐酸多巴酚丁胺治疗,实验组患者采用左西孟旦治疗。观察两组患者的治疗效果,包括治疗总有效率及治疗过程中不良反应发生情况,记录患者治疗后的心脏指数、心搏指数、心排出量、左心室舒张末径、左心室射血分数等指标变化,后采用电代学发光法检测试剂盒对患者的血N末端B型利钠肽水平进行测量。结果实验组患者的治疗总有效率为93.88%,显著高于参照组的67.35%,差异有统计学意义(P<0.05)。实验组患者的不良反应总发生率为8.16%(4/49),明显低于参照组的30.61%(15/49),差异有统计学意义(P<0.05)。实验组患者的心脏指数、心搏指数、心排出量及左心室射血分数均明显高于参照组,左心室舒张末径低于参照组,差异有统计学意义(P<0.05)。实验组患者的血N末端B型利钠肽水平为(1275.54±421.16)ng/L,显著低于参照组的(1852.44±425.43)ng/L,差异有统计学意义(P<0.05)。结论左西孟旦治疗难治性心力衰竭具有显著的效果,可准确改善其心脏各指标,并减少不良反应对其造成的负面影响,临床值得应用与推广。

Objective To study the clinical effect of Levosimendan in the treatment of refractory heart failure.Methods A total of 98 patients with refractory heart failure admitted to our hospital from September 2017 to June 2018 were randomly selected as the study subjects.They were divided into the reference group and the experimental group according to the randomized comprehensive balance method,with 49 cases in each group.Patients in the reference group were treated with Dobutamine Hydrochloride,and patients in the experimental group were treated with Levosimendan.The therapeutic effect of the two groups were observed,including the total effective rate of treatment and the occurrence of adverse reactions during the treatment.The cardiac index,heart rate index,cardiac output,left ventricular end diastolic diameter,left ventricular ejection fraction were recorded after treatment.The electron luminescence detection kit was used to measure the level of blood N-terminal B-type natriuretic peptide of the two groups.Results The total effective rate of treatment in the experimental group was 93.88%,which was significantly higher than that in the reference group(67.35%),and the difference was statistically significant(P<0.05).The total incidence rate of adverse reactions in the experimental group was 8.16%(4/49),which was significantly lower than that in the reference group accounting for 30.61%(15/49),and the difference was statistically significant(P<0.05).The cardiac index,heart rate index,cardiac output and left ventricular ejection fraction of the experimental group were significantly higher than those of the reference group,the left ventricular end-diastolic diameter was lower than that of the reference group,and the differences were statistically significant(P<0.05).The level of blood N-terminal B-type natriuretic peptide in the experimental group was(1275.54±421.16)ng/L,which was lower than that in the reference group of(1852.44±425.43)ng/L,and the difference was statistically significant(P<0.05).Conclusion Levosimendan has a significant effect in the treatment of refractory heart failure,and it can accurately improve the various indicators of the heart,and reduce the negative impact of adverse reactions,which is worthy of clinical application and promotion.